| Lessons learned from the clinical development and market authorization of Glybera LM Bryant, DM Christopher, AR Giles, C Hinderer, JL Rodriguez, JB Smith, ... Human gene therapy Clinical development 24 (2), 55-64, 2013 | 198 | 2013 |
| B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look JB Smith, C Stashwick, DJ Powell Jr Gynecologic oncology 134 (1), 181-189, 2014 | 73 | 2014 |
| Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma MK Panjwani, JB Smith, K Schutsky, J Gnanandarajah, CM O'connor, ... Molecular Therapy 24 (9), 1602-1614, 2016 | 66 | 2016 |
| Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor K Schutsky, DG Song, R Lynn, JB Smith, M Poussin, M Figini, Y Zhao, ... Oncotarget 6 (30), 28911, 2015 | 32 | 2015 |
| Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy JB Smith, E Lanitis, D Dangaj, E Buza, M Poussin, C Stashwick, ... Molecular Therapy 24 (11), 1987-1999, 2016 | 26 | 2016 |
| A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma DL Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ... Blood 128 (22), 2127-2127, 2016 | 23 | 2016 |
| CD4+ T-helper type 1 cytokines and trastuzumab facilitate CD8+ T-cell targeting of HER2/neu–expressing cancers J Datta, S Xu, C Rosemblit, JB Smith, JA Cintolo, DJ Powell, ... Cancer immunology research 3 (5), 455-463, 2015 | 21 | 2015 |
| A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes E Lanitis, JB Smith, D Dangaj, S Flingai, M Poussin, S Xu, BJ Czerniecki, ... Human gene therapy 25 (8), 730-739, 2014 | 15 | 2014 |
| PiggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype BE Barnett, DL Hermanson, JB Smith, X Wang, Y Tan, CE Martin, ... Target 929, K562, 2016 | 13 | 2016 |
| B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/-and Patient-Derived Multiple Myeloma Tumors R Mathur, BE Barnett, D Hermanson, J He, Z Zhang, S Rengarajan, ... Blood 130 (Suppl 1), 3068-3068, 2017 | 7 | 2017 |
| Production of Universal Anti-Bcma CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma X Wang, BE Barnett, C Martin, D Hermanson, X Li, J Smith, J Wu, ... Blood 130 (Suppl 1), 503-503, 2017 | 4 | 2017 |
| Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies JB Smith, MK Panjwani, K Schutsky, J Gnanandarajah, S Calhoun, ... Journal for immunotherapy of cancer 3 (S2), P123, 2015 | 3 | 2015 |
| Abstract A071: PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... Cancer Research 78 (16 Supplement), A071-A071, 2018 | 2 | 2018 |
| PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability D Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ... Cancer Research 77, 2017 | 2 | 2017 |
| High Fidelity Genome Editing Using NextGEN™ CRISPR (Clo51-dCas9) System for the Production of Allogeneic CAR-T Cells X Wang, X Li, B Barnett, C Martin, D Hermanson, J Smith, S Rengarajan, ... Journal of Clinical Oncology 35, 2017 | 2 | 2017 |
| P-BCMA-ALLO1—a non-viral allogeneic anti-BCMA CAR T therapy with potent anti-tumor function for the treatment of multiple myeloma M Richter, S Cranert, Y Tan, M Tong, C Domingo, E Argus, S Ibitokou, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 1 | 2019 |
| PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | 1 | 2017 |
| Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor N Mason, DJ Powell, MK Panjwani, J Smith US Patent App. 15/743,033, 2019 | | 2019 |
| A Novel MUC1-Specific CAR-T Therapy (P-MUC1C-101) for Treatment of Multiple Solid Tumors JB Smith, X Wang, Y Tan, R Codde, J Fritz, P Ghoroghchian, EM Ostertag, ... MOLECULAR THERAPY 27 (4), 268-269, 2019 | | 2019 |
| Gene Modification of Human T Cells via Piggyback Yields an Anti-BCMA CARTyrin Cellular Product with Durable Efficacy D Hermanson, B Barnett, X Wang, R Mathur, J He, S Rengarajan, X Li, ... MOLECULAR THERAPY 25 (5), 53-53, 2017 | | 2017 |
